This phase II trial, designed by Peking University People’s Hospital, is a randomized, open-label, multicenter study to assess the combination treatment of tacrolimus and danazol compared to danazol alone in steroid-resistant or relapsed ITP. Individuals with primary ITP between 18-70 years old and have relapsed or did not achieve a response with corticosteroids are eligible to enrol. Participants must have a platelet count less than 30x109/L at the time of enrollment. Individuals with secondary ITP, cancer, are pregnant, or were previously treated with danazol will not be ineligible to participate in this study.
China
Status: unknown